Nonclinical studies and clinical studies on fosfluconazole, a triazole antifungal agent (Prodif®)

Folia Pharmacologica Japonica

Volumn 124, Issue 1, 2004, Pages 41-51

  Kawakami, Yutaka ^a   Nagino, Kenji ^a   Shinkai, Keisuke ^a   Sobue, Satoshi ^a   Abe, Masaaki ^a   Ishiko, Junichi ^a  

^a PFIZER INC   (United States)

Author keywords

Candidiasis; Cryptococcosis; Fluconazole; Fosfluconazole; Prodrug

Indexed keywords

ALKALINE PHOSPHATASE; ANTIFUNGAL AGENT; FLUCONAZOLE; FOSFLUCONAZOLE; PHOSPHATE; PHOSPHORIC ACID; PRODRUG; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ENZYME MECHANISM; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; RASH; RAT STRAIN; REVIEW; VOMITING;

ADULT; ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; CLINICAL TRIALS; CRYPTOCOCCOSIS; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PHOSPHORIC ACID ESTERS; RATS;

EID: 3242795968     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.41     Document Type: Review

References (21)

1. Sobel JD for the Mycosis Study Group. Practice guidelines for the treatment of fungal infections. Clin Infect Dis. 2000;30:652.
2. Jpn J Med Mycol. 2000;41:71-76.
3. Beck-Sague CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247-1251.
4. Fraser VJ, Jones M, Dunkel J, Storfers S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, predictors of mortality. Clin Infect Dis. 1992;15:414-421.
5. Edwards JE Jr., Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis. 1997;25: 43-59.
6. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med. 1994;20:522-528.
7. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30:662-678.
8. Demajo WA, Guimond J-G, Rotstein C, Tweeddale M, and the Canadian Candidemia Advisory Group. Guidelines for the management of nosocomial Candida infections in non-neutropenic intensive care patients. Can J Infect Dis. 1997;8 Suppl B:3B-9B.
9. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000;30:710-718.
10. Jpn J Antibiot. 1997;50:669-682.
11. Jpn J Antibiot. 1998;51:721-734.
12. Bentley A, Butters M, Green SP, et al. The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Process Rev Des. 2002;6:109-112.
13. Jpn J Med Mycol. 1995;36:61-86.
14. Jpn J Med Myol. 1986; 27:190-197.
15. Fernley HN. Mammalian Alkaline Phosphatases. In: Boyer PD. editor. The Enzymes. 3rd ed. New York: Academic Press; 1971. Vol. 4, p. 417-447.
16. Meban C. Fine structural localization of alkaline phosphatase in the granular pneumonocytes of hamster lung. Histochemistry. 1975;43:367-372.
17. Schultz-Hector S, Balz K, Bohm M, Ikehara Y, Rieke L. Cellular localization of endothelial alkaline phosphatase reaction product and enzyme protein in the myocardium. J Histochem Cytochem. 1993;41:1813-1821.
18. Sobue S, Sekiguchi K, Shimatani K, Tan K. Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers. J Clin Pharmacol. 2004;44: 284-292.
19. Sobue S, Tan K, Layton G, Eve M, Sanderson JB. Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. Br J Clin Pharmacol. In press.
20. Sobue S, Tan K, Layton G, Leclerc V, Weil A. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol. 2004;57:773-784.
21. Berl T, Wilner KD, Gardner M, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol. 1995;6:242-247.